Most cases are discovered after some symptoms persist or more severe indications, such as jaundice, occur.
Some groups are looking for a better way to screen for pancreatic cancer, in hopes of catching it earlier. "There's a big push for developing a blood test," says Philip Arlen, president and CEO of Neogenix Oncology, Inc., a company that is looking into both diagnostics and treatment for pancreatic cancer. They have found a couple of genetic markers that are present in pancreatic cancer but not in normal tissue. The goal, says Arlen, who previously worked as a researcher at the National Cancer Institute, is to develop something akin to a PSA (prostate-specific antigen) test for prostate cancer.
There are clues, for example, that pancreatic cancer is not as much a sudden-onset disease as it often seems. After studying the accumulation of genetic mutations in pancreatic cancer tumors, researchers concluded that the disease takes an average of seven years to form a substantive tumor and closer to a decade to start moving to other organs, according to research published last October. Armed with that knowledge and the other finding of pre-malignant lesions, Arlen is hopeful that a non-invasive screening method will eventually be developed.
Widespread screening for more common cancers, such as breast, colon and prostate, have come under fire lately for leading to too many false positives and excessive follow-up treatment. With even rarer diseases, it is much trickier, Saltz points out, and would demand an exceedingly low false-positive rate. "Pancreatic cancer, although it's a terrifying disease, is rare," he says.
Trying new treatments
When pancreatic cancer is caught early, doctors will usually try to remove it surgically. As Saltz points out, however, the chances that it will come back in the next year or two are still relatively high. And the surgery itself is risky. The pancreas is lodged deep within the abdomen, surrounded by—and connected to—other major organs. "It's considered the magnum opus of a surgeon's repertoire," she says of partial pancreas removal, which is known as the Whipple procedure.
If the cancer has already spread, as it had in Steinman's case, the most common approach is chemotherapy, which "for regular pancreatic cancer, is not very effective," Saltz says. The mainstay is the chemo drug gemcitabine (Gemzar), which is one of the treatments Steinman received. In trials, some patients saw no benefit, but for a minority, it extended life by as long as a few years, suggesting that an essential molecular difference exists in their tumors.
Despite initial positive signs from chemo, and even when Steinman was doing better, "he felt like he was living with Damocles' sword over his neck—he never knew when it was going to come back," Schlesinger says. So he turned to what he knew: the immune system. "Ralph felt deeply that the key to a cure is getting the immune system revved up enough to fight off the tumor," Schlesinger says. "That wasn't such a simple thing to do."
Enlisting the immune system to fight off a cancer has long been a goal of researchers. The only immunotherapy currently approved for general use as cancer treatment is a drug for metastatic melanoma (ipilimumab, or Yervoy, approved in March). Saltz calls that approval good "evidence that it's an important avenue to explore" for other forms of cancer.
Scientist as test subject
When word spread that Steinman had pancreatic cancer, Schlesinger says, there was an outpouring of offers from fellow immunologists to try treatments they were working on—many having been made possible by Steinman's own discoveries about the immune system's dendritic cells. Not all the experimental drugs were meant to tackle pancreatic tumors; some were for skin or prostate cancer.
In all, Steinman tried eight different experimental therapies, Schlesinger says. But they were not under-the-table, backroom needle jabs, she is quick to point out. Each drug was already being tested on other patients in phase I clinical trails, and Schlesinger and Steinman went through great pains—and many hours—to ensure all of the proper institutional and government approvals were granted before he got the therapies.
The first treatment he got was a vaccine called GVAX, under development to treat prostate cancer. He also received a novel therapy that worked on a developmental pathway (the hedgehog signaling pathway) and two that were based on dendritic cells: one in which dendritic cells were created from his own blood cells that were then "pulsed with RNA that had been isolated from his tumor," Schlesinger explains; and another in which the dendritic cells were filled with "peptides that were from his own tumor." The hope was that the RNA and proteins from his tumor would help his dendritic cells stimulate his immune system to attack the cancer.
Arlen's group is testing, in a phase I trial, a monoclonal antibody to treat patients with the more common form of pancreatic cancer. Preliminary data show that the antibody finds its target with some 50 to 60 percent of patients with adenocarcinoma, he says. But that does not mean that it will leave them disease-free. And he hopes that a combination of the new approaches and the more standard drugs will yield even better results—a trial that they plan to start next year.
"I think it's far too early to say they have a treatment for any of these diseases," Saltz concludes.
Treating Jobs's cancer
Endocrine cancer, the variety Jobs had, is treated with a different variety of chemotherapy drugs. Two new drugs for this type were just approved by the U.S. Food and Drug Administration (FDA) earlier this year. Everolimus (sold as Afinitor) works by blocking the mTOR kinase target to alter cellular signaling and was approved in May. Sunitinib (sold as Sutent) blocks a vascular endothelial growth factor. "Neither is a cure—neither is a wonder drug for the disease," Saltz says. "Each provides some modest benefit. "
One form of treatment that is not recommended for most pancreatic cancer is a liver transplant. Media observers surmised that the transplant Jobs received in 2009 had been necessary because the cancer had spread to his liver. And although liver failure is a common cause of death for pancreatic cancer patients, because the liver is close to the pancreas and often gets invaded by the spreading cancer, getting a new one "is not an accepted standard form of treatment," he says, citing a lack of evidence to show that it works.